Potency of infused spinal antinociceptive agents is inversely related to magnitude of tolerance after continuous infusion

CW Stevens and TL Yaksh

Department of Pharmacology, Mayo Clinic, Rochester, Minnesota.

By employing a constant-rate (1 microliter/hr) constant-dose intrathecal infusion pump in rats, groups received a 7-day infusion of one of three concentrations (in nmol/hr) of each of the following receptor preferring ligands: morphine (mu: 2, 6, 20), sufentanil (mu: 0.06, 0.2, 0.6), DAMGO (mu: 0.1, 0.3, 1.0), DADLE (delta: 2, 6, 20) or ST-91 (alpha-2: 3, 10, 30). On day 7 the magnitude of tolerance was assessed by establishing i.t. dose-response curves for the effect of the chronic drug given as a bolus. Each infused animal was used for one bolus injection. It was observed that for all drugs, a parallel rightward shift in the dose-response curve was produced with the degree of shift proportional to the log of the infusion dose. Of particular significance was the finding that drugs differed significantly in the magnitude of the shift produced by the chronic infusion of equieffective concentrations. Thus, at the intermediate infusion dose, the degree of the shift in the bolus dose-response curve (i.e., magnitude of tolerance) for morphine, DADLE, ST-91, DAMGO and sufentanil was 55, 46, 29, 7 and 2, respectively. These data are interpreted to suggest that agents with high potency and a significant receptor reserve will produce a smaller shift in the dose-response curve (e.g., sufentanil and DAMGO) than the similar infusion of an equieffective dose of another agent with less potency and a smaller population of spare receptors (morphine).

Volume 250, Issue 1, pp. 1-8, 07/01/1989
Copyright © 1989 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				I. Kissin Tolerance to Opioid Analgesia: Why Do We Differ from Rats? Anesth. Analg., December 1, 2005; 101(6): 1727 - 1729. [Full Text] [PDF]

				G. Gu, I. Kondo, X.-Y. Hua, and T. L. Yaksh Resting and Evoked Spinal Substance P Release during Chronic Intrathecal Morphine Infusion: Parallels with Tolerance and Dependence J. Pharmacol. Exp. Ther., September 1, 2005; 314(3): 1362 - 1369. [Abstract] [Full Text] [PDF]

				Z. Zuo The Role of Opioid Receptor Internalization and {beta}-Arrestins in the Development of Opioid Tolerance Anesth. Analg., September 1, 2005; 101(3): 728 - 734. [Abstract] [Full Text] [PDF]

				J. Celver, M. Xu, W. Jin, J. Lowe, and C. Chavkin Distinct Domains of the {micro}-Opioid Receptor Control Uncoupling and Internalization Mol. Pharmacol., March 1, 2004; 65(3): 528 - 537. [Abstract] [Full Text] [PDF]

				R. M. Allen, A. L. Granger, and L. A. Dykstra The Competitive N-Methyl-D-aspartate Receptor Antagonist (-)-6-Phosphonomethyl-deca-hydroisoquinoline-3-carboxylic Acid (LY235959) Potentiates the Antinociceptive Effects of Opioids That Vary in Efficacy at the {micro}-Opioid Receptor J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 785 - 792. [Abstract] [Full Text] [PDF]

				L. J. Sim-Selley and B. R. Martin Effect of Chronic Administration of R-(+)-[2,3-Dihydro-5-methyl-3-[(morpholinyl)methyl]pyrrolo[1,2,3-de]-1,4-benzoxazinyl]-(1-naphthalenyl)methanone Mesylate (WIN55,212-2) or Delta 9-Tetrahydrocannabinol on Cannabinoid Receptor Adaptation in Mice J. Pharmacol. Exp. Ther., October 1, 2002; 303(1): 36 - 44. [Abstract] [Full Text] [PDF]

				P. Riba, Y. Ben, A. P. Smith, S. Furst, and N. M. Lee Morphine Tolerance in Spinal Cord Is Due to Interaction between {micro}- and delta -Receptors J. Pharmacol. Exp. Ther., January 1, 2002; 300(1): 265 - 272. [Abstract] [Full Text] [PDF]

				J. L. Wells, J. L. Bartlett, S. Ananthan, and E. J. Bilsky In Vivo Pharmacological Characterization of SoRI 9409, a Nonpeptidic Opioid {micro}-Agonist/delta -Antagonist That Produces Limited Antinociceptive Tolerance and Attenuates Morphine Physical Dependence J. Pharmacol. Exp. Ther., April 12, 2001; 297(2): 597 - 605. [Abstract] [Full Text]

				R. M. Allen and L. A. Dykstra Attenuation of {micro}-Opioid Tolerance and Cross-Tolerance by the Competitive N-Methyl-D-aspartate Receptor Antagonist LY235959 Is Related to Tolerance and Cross-Tolerance Magnitude J. Pharmacol. Exp. Ther., December 1, 2000; 295(3): 1012 - 1021. [Abstract] [Full Text]

				C. A. Fairbanks and G. L. Wilcox Spinal Antinociceptive Synergism between Morphine and Clonidine Persists in Mice Made Acutely or Chronically Tolerant to Morphine J. Pharmacol. Exp. Ther., March 1, 1999; 288(3): 1107 - 1116. [Abstract] [Full Text]

				A. Kovoor, J. P. Celver, A. Wu, and C. Chavkin Agonist Induced Homologous Desensitization of µ-Opioid Receptors Mediated by G Protein-Coupled Receptor Kinases Is Dependent on Agonist Efficacy Mol. Pharmacol., October 1, 1998; 54(4): 704 - 711. [Abstract] [Full Text]

				R. H. Arends, T. G. Hayashi, T. J. Luger, and D. D. Shen Cotreatment with Racemic Fenfluramine Inhibits the Development of Tolerance to Morphine Analgesia in Rats J. Pharmacol. Exp. Ther., August 1, 1998; 286(2): 585 - 592. [Abstract] [Full Text]

				S. A. Dunbar and I. J. Pulai Repetitive Opioid Abstinence Causes Progressive Hyperalgesia Sensitive to N-Methyl-D-aspartate Receptor Blockade in the Rat J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 678 - 686. [Abstract] [Full Text]

				J. Y. Xu, K. P. Hill, and J. M. Bidlack The Nitric Oxide/Cyclic GMP System at the Supraspinal Site Is Involved in the Development of Acute Morphine Antinociceptive Tolerance, J. Pharmacol. Exp. Ther., January 1, 1998; 284(1): 196 - 201. [Abstract] [Full Text]

				S. J. O'Neill, M. A. Collins, H. O. Pettit, R. W. McNutt, and K.-J. Chang Antagonistic Modulation Between the Delta Opioid Agonist BW373U86 and the Mu Opioid Agonist Fentanyl in Mice J. Pharmacol. Exp. Ther., July 1, 1997; 282(1): 271 - 277. [Abstract] [Full Text]

				S. A. Dunbar and T. L. Yaksh J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1219 - 1225. [Abstract] [Full Text]